Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance

Journal of Neurochemistry

Volumn , Issue , 2016, Pages 59-74

  Hernandez, Dena G ^a,b   Reed, Xylena ^a   Singleton, Andrew B ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

genetics; mendelian; Parkinsons Disease; risk alleles

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; PARKIN;

ATP13A2 GENE; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DJ 1 GENE; EXOME; FBXO7 GENE; GENE; GENE DUPLICATION; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC LINKAGE; GENETIC RISK; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LRRK2 GENE; MISSENSE MUTATION; MITOPHAGY; PARKIN GENE; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PINK1 GENE; PLA2G6 GENE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SNCA GENE; SYNAPSE; VPS35 GENE;

EID: 85027920043     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13593     Document Type: Review

References (204)

1. Aasly J. O., Vilarino-Guell C., Dachsel J. C. et al. (2010) Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Mov. Disord. 25, 2156–2163.
2. Abou-Sleiman P. M., Healyy D. G., Quinn N., Lees A. J. and Wood N. W. (2003) The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann. Neurol. 54, 283–286.
3. Aharon-Peretz J., Rosenbaum H. and Gershoni-Baruch R. (2004) Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 351, 1972–1977.
4. Alcalay R. N., Levy O. A., Waters C. C. et al. (2015) Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain 138(Pt 9), 2648–2658.
5. Alegre-Abarrategui J., Ansorge O., Esiri M. and Wade-Martins R. (2008) LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol. Appl. Neurobiol. 34, 272–283.
6. Athanassiadou A., Voutsinas G., Psiouri L., Leroy E., Polymeropoulos M. H., Ilias A., Maniatis G. M. and Papapetropoulos T. (1999) Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am. J. Hum. Genet. 65, 555–558.
7. Balsinde J. and Balboa M. A. (2005) Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. Cell. Signal. 17, 1052–1062.
8. Bardien S., Lesage S., Brice A. and Carr J. (2011) Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease. Parkinsonism Relat. Disord. 17, 501–508.
9. Beilina A., Rudenko I. N., Kaganovich A. et al. (2014) Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc. Natl Acad. Sci. USA 111, 2626–2631.
10. Bonifati V., Rizzu P., Squitieri F. et al. (2003) DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol. Sci. 24, 159–160.
11. Bonifati V., Rohe C. F., Breedveld G. J. et al. (2005) Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65, 87–95.
12. Bravo-San Pedro J. M., Niso-Santano M., Gomez-Sanchez R. et al. (2013) The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. Cell. Mol. Life Sci. 70, 121–136.
13. Brice A. (2005) Genetics of Parkinson's disease: LRRK2 on the rise. Brain 128(Pt 12), 2760–2762.
14. Bruggemann N., Hagenah J., Reetz K. et al. (2010) Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch. Neurol. 67, 1357–1363.
15. Burchell V. S., Nelson D. E., Sanchez-Martinez A. et al. (2013) The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy. Nat. Neurosci. 16, 1257–1265.
16. Burre J., Sharma M., Tsetsenis T., Buchman V., Etherton M. R. and Sudhof T. C. (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663–1667.
17. Canet-Aviles R. M., Wilson M. A., Miller D. W., Ahmad R., McLendon C., Bandyopadhyay S., Baptista M. J., Ringe D., Petsko G. A. and Cookson M. R. (2004) The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl Acad. Sci. USA 101, 9103–9108.
18. Chan D. K., Ng P. W., Mok V., Yeung J., Fang Z. M., Clarke R., Leung E. and Wong L. (2008) LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson's disease compared to late-onset patients. J. Neural. Transm. 115, 1275–1277.
19. Chartier-Harlin M. C., Kachergus J., Roumier C. et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167–1169.
20. Choi J. M., Woo M. S., Ma H. I. et al. (2008) Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics 9, 263–269.
21. Chouraki V. and Seshadri S. (2014) Genetics of Alzheimer's disease. Adv. Genet. 87, 245–294.
22. Consortium U. K. P. S. D., Wellcome Control Trust Case C., Spencer C. C. et al. (2011) Dissection of the genetics of Parkinson's disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21. Hum. Mol. Genet. 20, 345–353.
23. Correia Guedes L., Ferreira J. J., Rosa M. M., Coelho M., Bonifati V. and Sampaio C. (2010) Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. Parkinsonism Relat. Disord. 16, 237–242.
24. Cullen V., Lindfors M., Ng J. et al. (2009) Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol. Brain 2, 5.
25. Dehay B., Ramirez A., Martinez-Vicente M., Perier C., Canron M. H., Doudnikoff E., Vital A., Vila M., Klein C. and Bezard E. (2012) Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc. Natl Acad. Sci. USA 109, 9611–9616.
26. Di Fonzo A., Wu-Chou Y. H., Lu C. S. et al. (2006) A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7, 133–138.
27. Di Fonzo A., Dekker M. C., Montagna P. et al. (2009) FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 72, 240–245.
28. Doherty K. M. and Hardy J. (2013) Parkin disease and the Lewy body conundrum. Mov. Disord. 28, 702–704.
29. Doherty K. M., Silveira-Moriyama L., Parkkinen L. et al. (2013) Parkin disease: a clinicopathologic entity? JAMA Neurol. 70, 571–579.
30. Edwards T. L., Scott W. K., Almonte C. et al. (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 74, 97–109.
31. Farrer M., Wavrant-De Vrieze F., Crook R. et al. (1998) Low frequency of alpha-synuclein mutations in familial Parkinson's disease. Ann. Neurol. 43, 394–397.
32. Farrer M., Chan P., Chen R. et al. (2001) Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50, 293–300.
33. Farrer M., Kachergus J., Forno L. et al. (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55, 174–179.
34. Farrer M., Stone J., Mata I. F., Lincoln S., Kachergus J., Hulihan M., Strain K. J. and Maraganore D. M. (2005) LRRK2 mutations in Parkinson disease. Neurology 65, 738–740.
35. Farrer M. J., Stone J. T., Lin C. H., Dachsel J. C., Hulihan M. M., Haugarvoll K., Ross O. A. and Wu R. M. (2007) Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat. Disord. 13, 89–92.
36. Follett J., Norwood S. J., Hamilton N. A. et al. (2014) The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer. Traffic 15, 230–244.
37. Foroud T., Uniacke S. K., Liu L. et al. (2003) Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 60, 796–801.
38. Fortin D. L., Troyer M. D., Nakamura K., Kubo S., Anthony M. D. and Edwards R. H. (2004) Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 24, 6715–6723.
39. Fu X., Zheng Y., Hong H. et al. (2013) LRRK2 G2385R and LRRK2 R1628P increase risk of Parkinson's disease in a Han Chinese population from Southern Mainland China. Parkinsonism Relat. Disord. 19, 397–398.
40. Fuchs J., Nilsson C., Kachergus J. et al. (2007) Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68, 916–922.
41. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S. and Obata F. (2002) A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 51, 296–301.
42. Funayama M., Li Y., Tomiyama H., Yoshino H., Imamichi Y., Yamamoto M., Murata M., Toda T., Mizuno Y. and Hattori N. (2007) Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. NeuroReport 18, 273–275.
43. Fung H. C., Scholz S., Matarin M. et al. (2006) Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 5, 911–916.
44. Gegg M. E., Burke D., Heales S. J., Cooper J. M., Hardy J., Wood N. W. and Schapira A. H. (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72, 455–463.
45. Gitler A. D., Bevis B. J., Shorter J. et al. (2008) The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl Acad. Sci. USA 105, 145–150.
46. Gitler A. D., Chesi A., Geddie M. L. et al. (2009) Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet. 41, 308–315.
47. Gloeckner C. J., Schumacher A., Boldt K. and Ueffing M. (2009) The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J. Neurochem. 109, 959–968.
48. Greggio E. (2012) Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease. Biochem. Soc. Trans. 40, 1058–1062.
49. Greggio E., Taymans J. M., Zhen E. Y. et al. (2009) The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem. Biophys. Res. Commun. 389, 449–454.
50. Grunewald A., Voges L., Rakovic A. et al. (2010) Mutant Parkin impairs mitochondrial function and morphology in human fibroblasts. PLoS ONE 5, e12962.
51. Grunewald A., Arns B., Seibler P., Rakovic A., Munchau A., Ramirez A., Sue C. M. and Klein C. (2012) ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. Neurobiol. Aging 33, 1843e1-7.
52. Guerreiro R., Wojtas A., Bras J. et al. (2013) TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117–127.
53. Gusdon A. M., Zhu J., Van Houten B. and Chu C. T. (2012) ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. Neurobiol. Dis. 45, 962–972.
54. Haft C. R., dela Luz Sierra M., Bafford R., Lesniak M. A., Barr V. A. and Taylor S. I. (2000) Human orthologs of yeast vacuolar protein sorting proteins Vps 26, 29, and 35: assembly into multimeric complexes. Mol. Biol. Cell 11, 4105–4116.
55. Hamza T. H., Zabetian C. P., Tenesa A. et al. (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 42, 781–785.
56. Haugarvoll K. and Wszolek Z. K. (2009) Clinical features of LRRK2 parkinsonism. Parkinsonism Relat. Disord. 15(Suppl 3), S205–S208.
57. Healy D. G., Abou-Sleiman P. M., Ahmadi K. R., Muqit M. M., Bhatia K. P., Quinn N. P., Lees A. J., Latchmann D. S., Goldstein D. B. and Wood N. W. (2004) The gene responsible for PARK6 Parkinson's disease, PINK1, does not influence common forms of parkinsonism. Ann. Neurol. 56, 329–335.
58. Healy D. G., Falchi M., O'Sullivan S. S. et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7, 583–590.
59. Hedrich K., Kann M., Lanthaler A. J. et al. (2001) The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum. Mol. Genet. 10, 1649–1656.
60. Hedrich K., Eskelson C., Wilmot B. et al. (2004) Distribution, type, and origin of Parkin mutations: review and case studies. Mov. Disord. 19, 1146–1157.
61. Ibanez P., Bonnet A. M., Debarges B., Lohmann E., Tison F., Pollak P., Agid Y., Durr A. and Brice A. (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 1169–1171.
62. Ibanez P., Lesage S., Lohmann E., Thobois S., De Michele G., Borg M., Agid Y., Durr A., Brice A. and French Genetics Parkinson's Disease Study G. (2006) Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 129(Pt 3), 686–694.
63. Ibanez P., Lesage S., Janin S. et al. (2009) Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch. Neurol. 66, 102–108.
64. Ikeuchi T., Kakita A., Shiga A. et al. (2008) Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch. Neurol. 65, 514–519.
65. Johnson J., Paisan-Ruiz C., Lopez G. et al. (2007) Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation. Neurodegener. Dis. 4, 386–391.
66. Jonsson T., Stefansson H., Steinberg S. et al. (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368, 107–116.
67. Kachergus J., Mata I. F., Hulihan M. et al. (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet. 76, 672–680.
68. Kane L. A., Lazarou M., Fogel A. I., Li Y., Yamano K., Sarraf S. A., Banerjee S. and Youle R. J. (2014) PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J. Cell Biol. 205, 143–153.
69. Khan N. L., Graham E., Critchley P., Schrag A. E., Wood N. W., Lees A. J., Bhatia K. P. and Quinn N. (2003) Parkin disease: a phenotypic study of a large case series. Brain 126(Pt 6), 1279–1292.
70. Khan N. L., Jain S. and Lynch J. M. et al. (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128(Pt 12), 2786–2796.
71. Ki C. S., Stavrou E. F., Davanos N., Lee W. Y., Chung E. J., Kim J. Y. and Athanassiadou A. (2007) The Ala53Thr mutation in the alpha-synuclein gene in a Korean family with Parkinson disease. Clin. Genet. 71, 471–473.
72. Kim J. M., Lee J. Y., Kim H. J., Kim J. S., Shin E. S., Cho J. H., Park S. S. and Jeon B. S. (2010) The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population. Parkinsonism Relat. Disord. 16, 85–88.
73. Kinghorn K. J., Castillo-Quan J. I., Bartolome F. et al. (2015) Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction. Brain 138(Pt 7), 1801–1816.
74. Kinumi T., Kimata J., Taira T., Ariga H. and Niki E. (2004) Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 317, 722–728.
75. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y. and Shimizu N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605–608.
76. Klein C. and Schlossmacher M. G. (2006) The genetics of Parkinson disease: implications for neurological care. Nat. Clin. Pract. Neurol. 2, 136–146.
77. Klein C., Djarmati A., Hedrich K. et al. (2005a) PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. Eur. J. Hum. Genet. 13, 1086–1093.
78. Klein R. J., Zeiss C., Chew E. Y. et al. (2005b) Complement factor H polymorphism in age-related macular degeneration. Science 308, 385–389.
79. Kong S. M., Chan B. K., Park J. S. et al. (2014) Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes alpha-Synuclein externalization via exosomes. Hum. Mol. Genet. 23, 2816–2833.
80. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J. T., Schols L. and Riess O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106–108.
81. Kruger R., Vieira-Saecker A. M., Kuhn W. et al. (1999) Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann. Neurol. 45, 611–617.
82. Kumar K. R., Djarmati-Westenberger A. and Grunewald A. (2011) Genetics of Parkinson's disease. Semin. Neurol. 31, 433–440.
83. Kumar K. R., Weissbach A., Heldmann M. et al. (2012) Frequency of the D620N mutation in VPS35 in Parkinson disease. Arch. Neurol. 69, 1360–1364.
84. Lesage S., Durr A. and Brice A. (2006a) LRRK2 is a major gene in North African parkinsonism. Med. Sci. (Paris) 22, 470–471.
85. Lesage S., Durr A., Tazir M., Lohmann E., Leutenegger A. L., Janin S., Pollak P., Brice A. and French Genetics Parkinson's Disease Study G. (2006b) LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354, 422–423.
86. Lesage S., Magali P., Lohmann E., Lacomblez L., Teive H., Janin S., Cousin P. Y., Durr A., Brice A. and French Genetics Parkinson Disease Study G. (2007) Deletion of the parkin and PACRG gene promoter in early-onset parkinsonism. Hum. Mutat. 28, 27–32.
87. Lesage S., Condroyer C., Lannuzel A. et al. (2009) Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson's disease. J. Med. Genet. 46, 458–464.
88. Lesage S., Condroyer C., Klebe S., Honore A., Tison F., Brefel-Courbon C., Durr A., Brice A. and French Genetics Parkinson's Disease Study G. (2012) Identification of VPS35 mutations replicated in French families with Parkinson disease. Neurology 78, 1449–1450.
89. Li Y., Tomiyama H., Sato K. et al. (2005) Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. Neurology 64, 1955–1957.
90. Li C., Ting Z., Qin X., Ying W., Li B., Guo Qiang L., Jian Fang M., Jing Z., Jian Qing D. and Sheng Di C. (2007) The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease. Mov. Disord. 22, 2439–2443.
91. Li Y., Dunn L., Greggio E., Krumm B., Jackson G. S., Cookson M. R., Lewis P. A. and Deng J. (2009) The R1441C mutation alters the folding properties of the ROC domain of LRRK2. Biochim. Biophys. Acta 1792, 1194–1197.
92. Lorenzo-Betancor O., Samaranch L. and Ezquerra M. et al. (2012) LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p. S1761R mutation. Mov. Disord. 27, 146–151.
93. Lucking C. B., Durr A., Bonifati V. et al. (2000) Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 342, 1560–1567.
94. Ludolph A. C., Kassubek J., Landwehrmeyer B. G. et al. (2009) Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur. J. Neurol. 16, 297–309.
95. MacLeod D., Dowman J., Hammond R., Leete T., Inoue K. and Abeliovich A. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587–593.
96. MacLeod D. A., Rhinn H., Kuwahara T. et al. (2013) RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 77, 425–439.
97. Malik I., Turk J., Mancuso D. J., Montier L., Wohltmann M., Wozniak D. F., Schmidt R. E., Gross R. W. and Kotzbauer P. T. (2008) Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. Am. J. Pathol. 172, 406–416.
98. Manzoni C., Mamais A., Dihanich S., Abeti R., Soutar M. P., Plun–-Favreau H., Giunti P., Tooze S. A., Bandopadhyay R. and Lewis P. A. (2013) Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim. Biophys. Acta 1833, 2900–2910.
99. Maraganore D. M., de Andrade M., Lesnick T. G., Strain K. J., Farrer M. J., Rocca W. A., Pant P. V., Frazer K. A., Cox D. R. and Ballinger D. G. (2005) High-resolution whole-genome association study of Parkinson disease. Am. J. Hum. Genet. 77, 685–693.
100. Maraganore D. M., de Andrade M., Elbaz A. et al. (2006) Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296, 661–670.
101. Marongiu R., Brancati F., Antonini A. et al. (2007) Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. Hum. Mutat. 28, 98.
102. Martinat C., Shendelman S., Jonason A., Leete T., Beal M. F., Yang L., Floss T. and Abeliovich A. (2004) Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism. PLoS Biol. 2, e327.
103. Mata I. F., Kachergus J. M., Taylor J. P. et al. (2005) Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6, 171–177.
104. Mazzulli J. R., Xu Y. H., Sun Y., Knight A. L., McLean P. J., Caldwell G. A., Sidransky E., Grabowski G. A. and Krainc D. (2011) Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37–52.
105. Menzies F. M., Yenisetti S. C. and Min K. T. (2005) Roles of Drosophila DJ-1 in survival of dopaminergic neurons and oxidative stress. Curr. Biol. 15, 1578–1582.
106. Meulener M., Whitworth A. J., Armstrong-Gold C. E., Rizzu P., Heutink P., Wes P. D., Pallanck L. J. and Bonini N. M. (2005) Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr. Biol. 15, 1572–1577.
107. Mitsumoto A. and Nakagawa Y. (2001) DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic. Res. 35, 885–893.
108. Mitsumoto A., Nakagawa Y., Takeuchi A., Okawa K., Iwamatsu A. and Takanezawa Y. (2001) Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radic. Res. 35, 301–310.
109. Mizutani Y., Yokochi M. and Oyanagi S. (1991) Juvenile parkinsonism: a case with first clinical manifestation at the age of six years and with neuropathological findings suggesting a new pathogenesis. Clin. Neuropathol. 10, 91–97.
110. Morgan N. V., Westaway S. K., Morton J. E. et al. (2006) PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat. Genet. 38, 752–754.
111. Mori H., Hattori N. and Mizuno Y. (2003) Genotype-phenotype correlation: familial Parkinson disease. Neuropathology 23, 90–94.
112. Mortiboys H., Johansen K. K., Aasly J. O. and Bandmann O. (2010) Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75, 2017–2020.
113. Mubaidin A., Roberts E., Hampshire D., Dehyyat M., Shurbaji A., Mubaidien M., Jamil A., Al-Din A., Kurdi A. and Woods C. G. (2003) Karak syndrome: a novel degenerative disorder of the basal ganglia and cerebellum. J. Med. Genet. 40, 543–546.
114. Munoz E., Oliva R., Obach V., Marti M. J., Pastor P., Ballesta F. and Tolosa E. (1997) Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the alpha-synuclein gene in early onset patients. Neurosci. Lett. 235, 57–60.
115. Nagakubo D., Taira T., Kitaura H., Ikeda M., Tamai K., Iguchi-Ariga S. M. and Ariga H. (1997) DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem. Biophys. Res. Commun. 231, 509–513.
116. Nalls M. A., Duran R., Lopez G. et al. (2013) A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 70, 727–735.
117. Nalls M. A., Pankratz N., Lill C. M. et al. (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 46, 989–993.
118. Nalls M. A., McLean C. Y., Rick J. et al. (2015) Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol. 14, 1002–1009.
119. Narendra D., Tanaka A., Suen D. F. and Youle R. J. (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795–803.
120. Narendra D. P., Jin S. M., Tanaka A., Suen D. F., Gautier C. A., Shen J., Cookson M. R. and Youle R. J. (2010) PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 8, e1000298.
121. Nemani V. M., Lu W., Berge V., Nakamura K., Onoa B., Lee M. K., Chaudhry F. A., Nicoll R. A. and Edwards R. H. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 66–79.
122. Nichols R. J., Dzamko N., Morrice N. A. et al. (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem. J. 430, 393–404.
123. Nishioka K., Hayashi S., Farrer M. J. et al. (2006) Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann. Neurol. 59, 298–309.
124. Niu J., Yu M., Wang C. and Xu Z. (2012) Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein. J. Neurochem. 122, 650–658.
125. Nothwehr S. F., Ha S. A. and Bruinsma P. (2000) Sorting of yeast membrane proteins into an endosome-to-Golgi pathway involves direct interaction of their cytosolic domains with Vps35p. J. Cell Biol. 151, 297–310.
126. Nuytemans K., Theuns J., Cruts M. and Van Broeckhoven C. (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum. Mutat. 31, 763–780.
127. Nuytemans K., Bademci G., Inchausti V. et al. (2013) Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease. Neurology 80, 982–989.
128. Orenstein S. J., Kuo S. H., Tasset I. et al. (2013) Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 16, 394–406.
129. Ozelius L. J., Senthil G., Saunders-Pullman R. et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354, 424–425.
130. Paisan-Ruiz C., Jain S., Evans E. W. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595–600.
131. Paisan-Ruiz C., Nath P., Washecka N., Gibbs J. R. and Singleton A. B. (2008) Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. Hum. Mutat. 29, 485–490.
132. Paisan-Ruiz C., Bhatia K. P., Li A., Hernandez D., Davis M., Wood N. W., Hardy J., Houlden H., Singleton A. and Schneider S. A. (2009) Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann. Neurol. 65, 19–23.
133. Pankratz N., Pauciulo M. W., Elsaesser V. E., Marek D. K., Halter C. A., Wojcieszek J., Rudolph A., Shults C. W., Foroud T. and Nichols W. C. (2006) Mutations in DJ-1 are rare in familial Parkinson disease. Neurosci. Lett. 408, 209–213.
134. Pankratz N., Wilk J. B., Latourelle J. C. et al. (2009) Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet. 124, 593–605.
135. Papapetropoulos S., Paschalis C., Athanassiadou A., Papadimitriou A., Ellul J., Polymeropoulos M. H. and Papapetropoulos T. (2001) Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 70, 662–665.
136. Paravicini G., Horazdovsky B. F. and Emr S. D. (1992) Alternative pathways for the sorting of soluble vacuolar proteins in yeast: a vps35 null mutant missorts and secretes only a subset of vacuolar hydrolases. Mol. Biol. Cell 3, 415–427.
137. Parisiadou L., Xie C., Cho H. J. et al. (2009) Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci. 29, 13971–13980.
138. Park J. H., Wacholder S., Gail M. H., Peters U., Jacobs K. B., Chanock S. J. and Chatterjee N. (2010) Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat. Genet. 42, 570–575.
139. Park J. S., Blair N. F. and Sue C. M. (2015) The role of ATP13A2 in Parkinson's disease: clinical phenotypes and molecular mechanisms. Mov. Disord. 30, 770–779.
140. Periquet N. M., Latouche M. and Lohmann E. et al. (2003) Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain 126(Pt 6), 1271–1278.
141. Polymeropoulos M. H., Hurko O., Hsu F., Rubenstein J., Basnet S., Lane K., Dietz H., Spetzler R. F. and Rigamonti D. (1997a) Linkage of the locus for cerebral cavernous hemangiomas to human chromosome 7q in four families of Mexican-American descent. Neurology 48, 752–757.
142. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997b) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045–2047.
143. Pritchard J. K. and Cox N. J. (2002) The allelic architecture of human disease genes: common disease-common variant. or not? Hum. Mol. Genet. 11, 2417–2423.
144. Pulkes T., Papsing C., Mahasirimongkol S., Busabaratana M., Kulkantrakorn K. and Tiamkao S. (2011) Frequencies of LRRK2 variants in Thai patients with Parkinson's disease: evidence for an R1628P founder. J. Neurol. Neurosurg. Psychiatry 82, 1179–1180.
145. Puschmann A., Ross O. A., Vilarino-Guell C. et al. (2009) A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat. Disord. 15, 627–632.
146. Ramirez A., Heimbach A., Grundemann J. et al. (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38, 1184–1191.
147. Reich D. E. and Lander E. S. (2001) On the allelic spectrum of human disease. Trends Genet. 17, 502–510.
148. Requejo-Aguilar R., Lopez-Fabuel I., Jimenez-Blasco D., Fernandez E., Almeida A. and Bolanos J. P. (2015) DJ1 represses glycolysis and cell proliferation by transcriptionally up-regulating Pink1. Biochem. J. 467, 303–310.
149. Ross O. A., Braithwaite A. T., Skipper L. M. et al. (2008a) Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann. Neurol. 63, 743–750.
150. Ross O. A., Wu Y. R., Lee M. C. et al. (2008b) Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann. Neurol. 64, 88–92.
151. Ross O. A., Soto-Ortolaza A. I., Heckman M. G. et al. (2011) Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 10, 898–908.
152. Rubio J. P., Topp S., Warren L. et al. (2012) Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe. Hum. Mutat. 33, 1087–1098.
153. Satake W., Nakabayashi Y., Mizuta I. et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303–1307.
154. Scott W. K., Staijich J. M., Yamaoka L. H., Speer M. C., Vance J. M., Roses A. D. and Pericak-Vance M. A. (1997) Genetic complexity and Parkinson's disease. Deane Laboratory Parkinson Disease Research Group. Science 277, 387–388; author reply 389.
155. Scott W. K., Yamaoka L. H., Stajich J. M. et al. (1999) The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics 2, 191–192.
156. Scuderi S., La Cognata V., Drago F., Cavallaro S. and D'Agata V. (2014) Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain. Biomed. Res. Int. 2014, 690796.
157. Seaman M. N., McCaffery J. M. and Emr S. D. (1998) A membrane coat complex essential for endosome-to-Golgi retrograde transport in yeast. J. Cell Biol. 142, 665–681.
158. Shendelman S., Jonason A., Martinat C., Leete T. and Abeliovich A. (2004) DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol. 2, e362.
159. Shimura H., Hattori N., Kubo S. et al. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25, 302–305.
160. Shojaee S., Sina F., Banihosseini S. S., Kazemi M. H., Kalhor R., Shahidi G. A., Fakhrai-Rad H., Ronaghi M. and Elahi E. (2008) Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am. J. Hum. Genet. 82, 1375–1384.
161. Sidransky E., Samaddar T. and Tayebi N. (2009) Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 73, 1424–1425, author reply 1425-6.
162. Simon-Sanchez J., Schulte C., Bras J. M. et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308–1312.
163. Simon-Sanchez J., van Hilten J. J., van de Warrenburg B. et al. (2011) Genome-wide association study confirms extant PD risk loci among the Dutch. Eur. J. Hum. Genet. 19, 655–661.
164. Sina F., Shojaee S., Elahi E., Paisan-Ruiz C. (2009) R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family. Eur. J. Neurol. 16, 101–104.
165. Singleton A. and Gwinn-Hardy K. (2004) Parkinson's disease and dementia with Lewy bodies: a difference in dose? Lancet 364, 1105–1107.
166. Singleton A. and Hardy J. (2011) A generalizable hypothesis for the genetic architecture of disease: pleomorphic risk loci. Hum. Mol. Genet. 20(R2), R158-62.
167. Singleton A. B., Farrer M., Johnson J. et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
168. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839–840.
169. Spira P. J., Sharpe D. M., Halliday G., Cavanagh J. and Nicholson G. A. (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 49, 313–319.
170. Taira T., Saito Y., Niki T., Iguchi-Ariga S. M., Takahashi K. and Ariga H. (2004) DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 5, 213–218.
171. Takahashi H., Ohama E., Suzuki S., Horikawa Y., Ishikawa A., Morita T., Tsuji S. and Ikuta F. (1994) Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 44(3 Pt 1), 437–441.
172. Takahashi-Niki K., Niki T., Taira T., Iguchi-Ariga S. M. and Ariga H. (2004) Reduced anti-oxidative stress activities of DJ-1 mutants found in Parkinson's disease patients. Biochem. Biophys. Res. Commun. 320, 389–397.
173. Tan E. K., Shen H., Tan L. C. et al. (2005) The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci. Lett. 384, 327–329.
174. Tan E. K., Zhao Y., Skipper L. et al. (2007a) The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum. Genet. 120, 857–863.
175. Tan E. K., Zhao Y., Tan L., Lim H. Q., Lee J., Yuen Y., Pavanni R., Wong M. C., Fook-Chong S. and Liu J. J. (2007b) Analysis of LRRK2 Gly2385Arg genetic variant in non-Chinese Asians. Mov. Disord. 22, 1816–1818.
176. Tan E. K., Peng R., Wu Y. R., Wu R. M., Wu-Chou Y. H., Tan L. C., An X. K., Chen C. M., Fook-Chong S. and Lu C. S. (2009) LRRK2 G2385R modulates age at onset in Parkinson's disease: a multi-center pooled analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B, 1022–1023.
177. Tan E. K., Peng R., Teo Y. Y. et al. (2010) Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum. Mutat. 31, 561–568.
178. Tang B., Xiong H., Sun P. et al. (2006) Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum. Mol. Genet. 15, 1816–1825.
179. Tayebi N., Callahan M., Madike V., Stubblefield B. K., Orvisky E., Krasnewich D., Fillano J. J. and Sidransky E. (2001) Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol. Genet. Metab. 73, 313–321.
180. Tayebi N., Walker J., Stubblefield B., Orvisky E., LaMarca M. E., Wong K., Rosenbaum H., Schiffmann R., Bembi B. and Sidransky E. (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol. Genet. Metab. 79, 104–109.
181. Thayanidhi N., Helm J. R., Nycz D. C., Bentley M., Liang Y. and Hay J. C. (2010) Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol. Biol. Cell 21, 1850–1863.
182. Troiano A. R., Cazeneuve C., Le Ber I., Bonnet A. M., Lesage S. and Brice A. (2008) Re: alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology 71, 1295; author reply 1295.
183. Tsuji S., Choudary P. V., Martin B. M., Stubblefield B. K., Mayor J. A., Barranger J. A. and Ginns E. I. (1987) A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. N. Engl. J. Med. 316, 570–575.
184. Uchiyama T., Ikeuchi T., Ouchi Y. et al. (2008) Prominent psychiatric symptoms and glucose hypometabolism in a family with a SNCA duplication. Neurology 71, 1289–1291.
185. Usenovic M., Tresse E., Mazzulli J. R., Taylor J. P. and Krainc D. (2012) Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. J. Neurosci. 32, 4240–4246.
186. Valente E. M., Bentivoglio A. R., Dixon P. H., Ferraris A., Ialongo T., Frontali M., Albanese A. and Wood N. W. (2001) Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Genet. 68, 895–900.
187. Valente E. M., Abou-Sleiman P. M., Caputo V. et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158–1160.
188. Vilarino-Guell C., Wider C., Ross O. A. et al. (2011) VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 89, 162–167.
189. Vitte J., Traver S., Maues Paula De A., Lesage S., Rovelli G., Corti O., Duyckaerts C. and Brice A. (2010) Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J. Neuropathol. Exp. Neurol. 69, 959–972.
190. Wang C., Cai Y., Zheng Z. et al. (2012) Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants. Parkinsonism Relat. Disord. 18, 958–963.
191. de van Warrenburg B. P., Lammens M., Lucking C. B., Denefle P., Wesseling P., Booij J., Praamstra P., Quinn N., Brice A. and Horstink M. W. (2001) Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56, 555–557.
192. West A. B., Maraganore D., Crook J., Lesnick T., Lockhart P. J., Wilkes K. M., Kapatos G., Hardy J. A. and Farrer M. J. (2002) Functional association of the parkin gene promoter with idiopathic Parkinson's disease. Hum. Mol. Genet. 11, 2787–2792.
193. Winner B., Jappelli R., Maji S. K. et al. (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl Acad. Sci. USA 108, 4194–4199.
194. Wu X., Tang K. F., Li Y. et al. (2012) Quantitative assessment of the effect of LRRK2 exonic variants on the risk of Parkinson's disease: a meta-analysis. Parkinsonism Relat. Disord. 18, 722–730.
195. Wu-Chou Y. H., Chen Y. T., Yeh T. H. et al. (2013) Genetic variants of SNCA and LRRK2 genes are associated with sporadic PD susceptibility: a replication study in a Taiwanese cohort. Parkinsonism Relat. Disord. 19, 251–255.
196. Xu J., Zhong N., Wang H., Elias J. E., Kim C. Y., Woldman I., Pifl C., Gygi S. P., Geula C. and Yankner B. A. (2005) The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum. Mol. Genet. 14, 1231–1241.
197. Yang J., Benyamin B., McEvoy B. P. et al. (2010) Common SNPs explain a large proportion of the heritability for human height. Nat. Genet. 42, 565–569.
198. Yoshino H., Tomiyama H., Tachibana N., Ogaki K., Li Y., Funayama M., Hashimoto T., Takashima S. and Hattori N. (2010) Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 75, 1356–1361.
199. Zabetian C. P., Yamamoto M., Lopez A. N. et al. (2009) LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease. Mov. Disord. 24, 1034–1041.
200. Zarranz J. J., Alegre J., Gomez-Esteban J. C. et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164–173.
201. Zhou W., Zhu M., Wilson M. A., Petsko G. A. and Fink A. L. (2006) The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J. Mol. Biol. 356, 1036–1048.
202. Zhou Z. D., Xie S. P., Sathiyamoorthy S. et al. (2015) F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy. Hum. Mol. Genet. 24, 6314–6330.
203. Zimprich A., Biskup S., Leitner P. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601–607.
204. Zimprich A., Benet-Pages A., Struhal W. et al. (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 89, 168–175.